The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 359:305-306 July 17, 2008 Number 3
NextNext

Reducing Antibody Levels in Patients Undergoing Transplantation
Ron Shapiro, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Vo, A. A.
-PubMed Citation
The advent of solid-organ transplantation for the treatment of patients with end-stage organ failure has been one of the most exciting medical advances in the late 20th and early 21st centuries. Thousands of lives have been saved or improved by transplantation, allowing terminally ill patients to rejoin society, work productively, and have a meaningful life.1,2

Unfortunately, transplantation has been an imperfect and expensive therapy. The financial burden of transplantation has limited its widespread application in the developed world; furthermore, therapeutic failure occurs all too often, owing to side effects or inadequacy of immunosuppression. Fortunately, in recent years, the potency of . . . [Full Text of this Article]


Source Information

From the Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.